SEATTLE, Sept. 18 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (Nasdaq: ZGEN - News) today announced detailed results from its pivotal Phase 3 trial of recombinant human Thrombin (rhThrombin) as an aid to controlling bleeding during surgery. The trial compared rhThrombin to bovine thrombin. As announced on September 5th 2006, both the primary and secondary endpoints of the study were met. rhThrombin demonstrated comparable efficacy and a superior immunogenicity profile as compared to bovine thrombin. Both treatments were well tolerated and exhibited similar adverse event profiles in this study.
